Exogenously administered recombinant A1M (rA1M) has previously been shown to have a therapeutic effect against organ damage induced by cell-free haemoglobin in organs such as placenta and kidneys, both ex vivo29 and in vivo in other less specific preeclampsia animal models30,31. Here, AMBP is linked to preeclampsia.